These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35788089)

  • 1. Bile acids and sphingolipids in non-alcoholic fatty liver disease.
    Jackson KG; Way GW; Zhou H
    Chin Med J (Engl); 2022 May; 135(10):1163-1171. PubMed ID: 35788089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.
    Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?
    Chávez-Talavera O; Haas J; Grzych G; Tailleux A; Staels B
    Curr Opin Lipidol; 2019 Jun; 30(3):244-254. PubMed ID: 30893108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease.
    Sciarrillo CM; Keirns BH; Koemel NA; Anderson KL; Emerson SR
    Liver Int; 2021 May; 41(5):894-904. PubMed ID: 33506572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease: Insights from sphingolipidomics.
    Montefusco DJ; Allegood JC; Spiegel S; Cowart LA
    Biochem Biophys Res Commun; 2018 Oct; 504(3):608-616. PubMed ID: 29778532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
    Jiao TY; Ma YD; Guo XZ; Ye YF; Xie C
    Acta Pharmacol Sin; 2022 May; 43(5):1103-1119. PubMed ID: 35217817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Presence of Periodontitis Exacerbates Non-Alcoholic Fatty Liver Disease via Sphingolipid Metabolism-Associated Insulin Resistance and Hepatic Inflammation in Mice with Metabolic Syndrome.
    Lu Z; Li Y; Chowdhury N; Yu H; Syn WK; Lopes-Virella M; Yilmaz Ö; Huang Y
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.
    Gottlieb A; Canbay A
    Cells; 2019 Oct; 8(11):. PubMed ID: 31671697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice.
    Wang R; Ren Y; Bao T; Wang T; Li Y; Liu Y; Zhang X; Yang S; Wang H
    Biochem Biophys Res Commun; 2022 Apr; 600():156-162. PubMed ID: 35240510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease.
    Nikolaou N; Gathercole LL; Marchand L; Althari S; Dempster NJ; Green CJ; van de Bunt M; McNeil C; Arvaniti A; Hughes BA; Sgromo B; Gillies RS; Marschall HU; Penning TM; Ryan J; Arlt W; Hodson L; Tomlinson JW
    Metabolism; 2019 Oct; 99():67-80. PubMed ID: 31330134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the Sphingolipidome in NAFLD.
    Montefusco D; Lambert J; Anderson A; Allegood J; Cowart LA
    Methods Mol Biol; 2022; 2455():279-303. PubMed ID: 35213002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chin brick tea [Camellia sinensis (L.) Kuntze] on lipid metabolism and inflammation by modulating intestinal flora and bile acids in mice with non-alcoholic fatty liver disease.
    Jin C; Zhou T; Duan Z; Deng Y; Zhang X; Xiao C; He J; He G; Zhou Y; Li S
    J Ethnopharmacol; 2024 Jan; 318(Pt B):116950. PubMed ID: 37506781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. THE ROLE OF BILE ACIDS IN THE REGULATION OF LIPID AND CARBOHYDRATE METABOLISM IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES TYPE2.
    Zvenigorodskaya LA; Petrakov AV; Nilova TV; Varvanina GG; Lychkova AE
    Eksp Klin Gastroenterol; 2016; (11):31-34. PubMed ID: 29889442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
    Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
    Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
    Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H
    Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal aberrant sphingolipid metabolism shaped-gut microbiome and bile acids metabolome in the development of hepatic steatosis.
    Miao RR; Zhan S; Cui SX; Qu XJ
    FASEB J; 2022 Aug; 36(8):e22398. PubMed ID: 35792869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.